drughunter.com
< 1 minute read
Sep. 6, 2024

Patent Highlight: New Chemical Matter in the NLRP3 Space

Author:  
Reviewer:  
Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

Patent Highlight: Tau-Targeting Heterobifunctional Degraders from Arvinas for Neurological Diseases

This article highlights a patent application from Arvinas that discloses the biological activity of compounds that act as tau-targeting heterobifunctional degraders, providing a summary of key data for selected molecules disclosed in the patent application.

Patent Highlights: Allosteric AR Modulators, Glycogen Synthase Inhibitors, and More

This article highlights million-dollar molecules that were recently in the news with related patent applications that give clues to their structures and properties. This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, brain-penetrant HER2 and ROCK2 inhibitors, and MDM2 degraders.

Patent Highlight: How Might Puhe BioPharma’s WRN Helicase Inhibitors Differentiate from Novartis’?

This article highlights a patent application from Puhe BioPharma that discloses the biological activity of compounds that act as WRN helicase inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

October 2024 Annotated Searchable Patent Table

Check out our searchable, annotated database featuring our curated selection of the most important drug discovery patents published in October 2024.

June 2024 Patent Highlights: GLP-1R Agonists, Polθ Inhibitors, Non-Ab PD-L1 Inhibitors, and More!

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in June 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as synthetically lethal Polθ inhibitors, SARM1 inhibitors for neurodegenerative indications, and our best guess at the identity of Gilead’s small molecule GLP-1R agonist GS-4571